8K - 2014 Q4 Earnings Release


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 12, 2015
 
Intermolecular, Inc.
(Exact Name of Registrant as Specified in Charter)
 
 
 
 
Delaware
001-35348
20-1616267
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
 
 

3011 N. First Street
San Jose, California
95134
(Address of Principal Executive Offices)
(Zip Code)

(408) 582-5700
(Registrant’s Telephone Number, Including Area Code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a‑12)
¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





ITEM  2.02.         RESULTS OF OPERATIONS AND FINANCIAL CONDITION
 
On February 12, 2015, Intermolecular, Inc. announced its financial results for the fourth quarter of fiscal 2014, ended December 31, 2014. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information furnished in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
 

ITEM  9.01.         FINANCIAL STATEMENTS AND EXHIBITS
 
(d) Exhibits
 
The following exhibit relating to Item 2.02 shall be deemed to be furnished and not filed:
 
99.1        Press Release dated February 12, 2015, entitled “Intermolecular Announces Full Year and Fourth Quarter 2014 Results”


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
INTERMOLECULAR, INC.
 
 
 
Date: February 12, 2015
By:
/s/ Bruce M. McWilliams
 
 
Bruce M. McWilliams
 
 
President and Chief Executive Officer